(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 695.4MM | -5% |
Gross Profit | 230.2MM | -17% |
Cost Of Revenue | 465.2MM | +3% |
Operating Income | 122.8MM | -24% |
Operating Expenses | 107.4MM | - |
Net Income | 115.3MM | -16% |
R&D | 17.6MM | -4% |
G&A | 86.7MM | -4% |
Interest Expense | 1.6MM | +33% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2024 Earnings Call Transcript April 25, 2024 West Pharmaceutical Services, Inc. beats earnings expectations. Reported EPS is $1.56, expectations were $1.26. West Pharmaceutical Services, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Bank of America Securities Healthcare Conference in Las Vegas, NV on Tuesday, May 14, 2024, at 11:20 AM PT.
West Pharmaceutical Services, Inc. ( NYSE:WST ) just released its latest first-quarter results and things are looking...
Unraveling the Financial and Strategic Position of WST Post Q1 2024 Results
West Pharmaceutical Services ( NYSE:WST ) First Quarter 2024 Results Key Financial Results Revenue: US$695.4m (down...
Despite a dip in Q1 performance, West Pharmaceutical projects a robust year with strategic expansions and improved guidance.
West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Company Reaffirms Full-Year Guidance and Raises EPS Outlook
West Pharmaceutical (WST) delivered earnings and revenue surprises of 20.93% and 3.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to manufacture injectable therapies. The company expects sales growth to ramp up as the year progresses, partly due to a surge in demand for components used in the packaging of newer treatments, including Novo Nordisk's diabetes drug Ozempic, weight-loss drug Wegovy, and Eli Lilly's diabetes drug Mounjaro. CEO Eric Green said ...